INmune Bio, Inc. (INMB) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.8x

Market Cap

$67.72M

MomentumView details →

1D Return

+7.49%

YTD Return

+50.32%

RSI (14)

60.1

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.8x

Market Cap

$67.72M

RSI (14)

60.1

MomentumView details →

1D Return

+7.49%

YTD Return

+50.32%

SummaryUpdated Jun 1, 2026

INmune Bio, Inc. (NASDAQ:INMB) is a clinical-stage immunotherapy company founded in 2015 and headquartered in Boca Raton, Florida. The company went public in February 2019 and focuses on developing innovative treatments that reprogram the patient's innate immune system to combat disease. INmune Bio operates three distinct therapeutic platforms targeting neuroinflammation in Alzheimer's disease, oncology applications through novel NK cell therapy, and rare diseases affecting skin integrity.

Ask drillr about INmune Bio, Inc. →

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−90.44%

ROA (TTM)

−68.60%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

−100.00%

EPS YoY

+72.29%

FCF YoY

—

Revenue CAGR 3Y

−48.87%

EPS CAGR 3Y

+11.85%

EBITDA YoY

+53.44%

EarningsView details →

EPS (Actual)

−$0.05

EPS Surprise

75.81%

Beats (12Q)

7/12

Next Q EPS Est

−$0.15

Avg Surprise (4Q)

36.88%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.07x

Current Ratio

4.04x

Quick Ratio

4.04x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−18.42M

Op. CF (TTM)

−14.97M

Next earningsOct 29, 2026 →

Latest newsMore news →

INmune Bio submitted an Orphan Drug Designation application and a pre-MAA Scientific Advice package to the European Medicines Agency for Ebstrocel in recessive dystrophic epidermolysis bullosa, supporting a planned EU marketing authorization application in Q1 2027.10d ago

INmune Bio plans to file for conditional approval of its Ebstrocel cell therapy in the United Kingdom by the end of Q3 or early Q4 2026.29d ago

Similar companies

Aptorum Group LimitedAPM CollPlant Biotechnologies Ltd.CLGN XBiotech Inc.XBIT Heron Therapeutics, Inc.HRTX Boundless Bio, Inc.BOLD Spero Therapeutics, Inc.SPRO Find similar companies →

Latest newsMore news →

INmune Bio submitted an Orphan Drug Designation application and a pre-MAA Scientific Advice package to the European Medicines Agency for Ebstrocel in recessive dystrophic epidermolysis bullosa, supporting a planned EU marketing authorization application in Q1 2027.10d ago INmune Bio plans to file for conditional approval of its Ebstrocel cell therapy in the United Kingdom by the end of Q3 or early Q4 2026.29d ago